Can neural autoantibodies disrupt receptor and synaptic signaling without proving autoimmune encephalitis?

Neural autoantibodies to neuronal cell-surface and synaptic targets are biologically capable of producing clinically relevant dysfunction, but an antibody result—especially in serum—must be separated from a diagnosis of autoimmune encephalitis.

Functional and synaptic effects

• Patient-derived antibodies can directly impair receptor-mediated signaling. GlyR antibodies suppress glycinergic synaptic currents, including with monovalent Fab fragments, supporting direct receptor interference rather than requiring receptor cross-linking or internalization.
• GABA(_A)-receptor antibodies reduce inhibitory GABAergic currents without detectable receptor internalization; GABA(_B)-receptor antibodies can functionally block signaling.
• CASPR2 antibodies have been associated with reduced AMPA-receptor clusters and AMPAR-mediated currents, as well as reduced Kv1 expression/function and increased neuronal excitability. Proposed mechanisms include disrupted CASPR2–contactin-2 interactions and altered channel/receptor trafficking.
• Thus, pathogenic effects are target-specific and may involve direct antagonism, altered synaptic organization/trafficking, or—less firmly for dopamine D1 antibodies—receptor activation.

Diagnostic interpretation

• Serum positivity is a supporting finding, not proof of pathogenic autoimmune encephalitis. Diagnosis requires a compatible encephalitic phenotype, exclusion of alternatives, and supportive objective CNS evidence such as CSF inflammation or MRI abnormalities.
• Specimen performance is antibody-dependent: CSF is particularly important for NMDAR antibodies, while serum can be more sensitive for LGI1 and CASPR2. Nonetheless, isolated serum results require phenotype correlation.
• Independent confirmation is consequential: tissue-based confirmation increased the positive predictive value of serum NMDAR cell-based-assay results from 69.7% to 97.1%. In one cohort, 61.8% of positive neural-antibody results were judged false positives, 95.2% from serum-only testing.

Bottom line

• Neural surface autoantibodies can disrupt receptor and synaptic function, but serum antibody positivity alone should prompt paired CSF testing when appropriate, confirmatory assays, and phenotype-driven clinical assessment—not establish autoimmune encephalitis.